Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment […]
The European Union on May 6 backed a U.S. proposal to discuss waiving patent protections for Covid-19 vaccines, but drugmakers and some other governments opposed the idea, saying it would not solve global inoculation shortages.
Manufacturing capacity and ingredients shortages are the main bottlenecks to expanding Covid-19 vaccine production, several global drug groups said on March 9, not patents that some critics are demanding be removed.
BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.
Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.
